Gregg Blevins

TL;DR: Daclizumab monotherapy is effective in most patients who experienced persistent MS disease activity with interferon beta therapy and pilot biomarkers were identified that can differentiate between full and partial dacluzumab responders.

TL;DR: The risk of conversion from a clinically isolated syndrome to multiple sclerosis was significantly lower with minocycline than with placebo over 6 months but not over 24 months.

TL;DR: This work validates the accuracy of QSM for brain iron mapping and also confirms ferric iron as the dominant susceptibility source in subcortical GM, by demonstrating high linear correlation ofQSM to Perls' ferricIron staining.

TL;DR: The incidence of new-onset inflammatory disease outside of the central nervous system in a subset of patients, however, warrants further studies to examine the possibility of compartmental differences in the capacity to maintain tolerance in the setting of reduced CD4+CD25+ Treg.

TL;DR: Daclizumab monotherapy inhibits formation of MS plaques in patients with RRMS and immunoregulatory NK cells may suppress activation of pathogenic immune responses directly in the CNS compartment.